Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...

The castration-sensitive prostate cancer market presents opportunities driven by rising prostate cancer incidences, an aging population, growing awareness, and improved early diagnosis. Successive ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

ACE-106 demonstrated notable anti-tumour activity across different tumour types.

—This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

Bayer failed to persuade a federal judge to grant a preliminary injunction in its lawsuit accusing drugmaker Johnson & ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...